Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AKTS | PRESS-RELEASE | neutral | 4/10 | Aktis Oncology announced upcoming ASCO poster presentations showcasing clinical imaging and dosimetry data for AKY-2519, | Apr 21, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix Pharmaceuticals announced that safety and dosimetry data from Part 1 of its Phase 3 ProstACT Global trial for TLX5 | Apr 21, 2026 |
| RAPP | PRESS-RELEASE | bullish | 8/10 | Rapport Therapeutics announced positive follow-up data from its Phase 2a trial of RAP-219 in focal onset seizures, showi | Apr 21, 2026 |
| OPK | PRESS-RELEASE | neutral | 1/10 | OPKO Health, Inc. announced it will report its Q1 2026 results on April 28, 2026. | Apr 21, 2026 |
| IMRX | PRESS-RELEASE | bullish | 7/10 | Immuneering Corporation announced that updated Phase 2a data from an expanded cohort of 55 first-line pancreatic cancer | Apr 21, 2026 |
| FHTX | PRESS-RELEASE | bullish | 7/10 | Foghorn Therapeutics presented new preclinical data at AACR 2026 showing complete and durable tumor regression with its | Apr 21, 2026 |
| OLMA | PRESS-RELEASE | neutral | 4/10 | Olema Oncology announced upcoming presentations of initial Phase 1 data for OP-3136 and a trial-in-progress overview of | Apr 21, 2026 |
| CYTK | PRESS-RELEASE | neutral | 1/10 | Cytokinetics, Incorporated announced it will report its Q1 results on May 5, 2026. | Apr 21, 2026 |
| BLTE | PRESS-RELEASE | neutral | 5/10 | Belite Bio announced the initiation of a rolling NDA submission to the FDA for tinlarebant, a potential treatment for St | Apr 21, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines announced that detailed results from its Phase 3 RASolute 302 trial of daraxonrasib in metastatic p | Apr 21, 2026 |
| BDTX | PRESS-RELEASE | bullish | 7/10 | Black Diamond Therapeutics announced upcoming presentations of Phase 2 data for silevertinib in non-small cell lung canc | Apr 21, 2026 |
| REGN | PRESS-RELEASE | bullish | 8/10 | Regeneron announced positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy for generaliz | Apr 21, 2026 |
| ZNTL | PRESS-RELEASE | neutral | 4/10 | Zentalis Pharmaceuticals announced that data from Part 1 of its MUIR trial, evaluating azenosertib in combination with p | Apr 21, 2026 |
| IMTX | PRESS-RELEASE | bullish | 7/10 | Immatics announced that four of its abstracts have been accepted for oral presentation at the 2026 ASCO Annual Meeting, | Apr 21, 2026 |
| NXTC | PRESS-RELEASE | neutral | 4/10 | NextCure announced that Phase 1 data for SIM0505, an investigational antibody-drug conjugate targeting CDH6 in solid tum | Apr 21, 2026 |
| APRE | PRESS-RELEASE | bullish | 7/10 | Aprea Therapeutics announced that early results from the first-in-human Phase 1 trial of its WEE1 inhibitor APR-1051 wil | Apr 21, 2026 |
| PACB | PRESS-RELEASE | neutral | 3/10 | PacBio announced that Lucid Genomics has joined its PacBio Compatible partner program, integrating its cloud-native bioi | Apr 21, 2026 |
| GEVO | PRESS-RELEASE | neutral | 1/10 | Gevo, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 21, 2026 |
| ENLV | PRESS-RELEASE, 6-K | bullish | 7/10 | Enlivex announced regulatory approval from Denmark's DKMA to initiate its Phase 2b trial of Allocetra for moderate-to-se | Apr 21, 2026 |
| DERM | PRESS-RELEASE | bullish | 6/10 | Journey Medical Corporation announced that approximately 85% of commercial lives in the U.S. now have access to its rosa | Apr 21, 2026 |
| PLYX | PRESS-RELEASE | bullish | 7/10 | Polaryx Therapeutics announced that the FDA granted Fast Track Designation (FTD) to its lead candidate PLX-200 for the t | Apr 21, 2026 |
| CELU | PRESS-RELEASE | neutral | 5/10 | { "summary": "Celularity Inc. (CELU) announced the closing of a transaction with NexGel, Inc., selling its biomaterial | Apr 21, 2026 |
| ALLO | PRESS-RELEASE | bullish | 7/10 | Allogene Therapeutics announced regulatory clearance to expand its pivotal Phase 2 ALPHA3 trial of cemacabtagene anseged | Apr 21, 2026 |
| KRYS | PRESS-RELEASE | neutral | 1/10 | Krystal Biotech, Inc. announced it will report its Q1 2026 results on May 4, 2026. | Apr 21, 2026 |
| HUMA | PRESS-RELEASE | bullish | 7/10 | Humacyte's Marketing Authorization Application (MAA) for its acellular tissue engineered vessel (Symvess) has been accep | Apr 21, 2026 |
| CRVS | PRESS-RELEASE | neutral | 4/10 | Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clinical data for soqueli | Apr 21, 2026 |
| BCTXL | PRESS-RELEASE | bullish | 7/10 | BriaCell Therapeutics presented positive preclinical data for its Bria-OTS+ immunotherapy platform at the 2026 AACR Annu | Apr 21, 2026 |
| RZLT | PRESS-RELEASE | bearish | 5/10 | Rezolute (RZLT) announced clinical data presentation at an upcoming medical conference but did not report financial resu | Apr 21, 2026 |
| BIOA | PRESS-RELEASE | bullish | 8/10 | BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsC | Apr 21, 2026 |
| EPRX | PRESS-RELEASE | bullish | 8/10 | Eupraxia Pharmaceuticals released 36-week data from Cohort 9 of its RESOLVE trial, showing robust and sustained symptom | Apr 21, 2026 |